VSBLTY CEO REPORTS ON COMPANY IMPLEMENTATION OF AI AND MACHINE LEARNING TECHNOLOGY
Philadelphia, PA, June 13, 2019 (GLOBE NEWSWIRE) -- Jay Hutton, co-founder & CEO of VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt: 5VS) (OTC: VSBGF), a leading retail software and technology company, today reported on the recent progress of the company in selling its artificial intelligence and machine learning technology.
“We have been working hard to lead the way in deploying our software in various activations that are monumental in the effect they have on driving innovation in both the retail and security worlds,” Hutton said.
Strategically, VSBLTY’s efforts have been focused on force multipliers. “The channel partners we have selected,” Hutton stated,” are dominant players in each of their selected categories. Our alignment with these companies brings to them world class software, expertise and scalable solutions. In return, VSBLTY gets a rapid deployment capability and an acceleration capacity that we could never achieve ourselves,” he explained.
“We have been fortunate to join forces with many of the largest, most influential mass integrators of their class,” Hutton said. He offered some highlights of what VSBLTY teams are working to accomplish to maintain its leadership position and help its clients drive innovation and ROI.
Key Commercial Contracts
VSBLTY has signed its first large deployment using vending machines in South Africa, which is slated to begin generating revenue by July. This business, referred by Intel (NYSE: INTC), replaces the Intel AIM software suite that previously provided data derived from computer vision, which has been discontinued.
VSBLTY technology has been deployed—and producing revenue—in conjunction with a large, world-class, integrated, point of purchase (POP) display manufacturer that works on behalf of many Fortune 50 consumer package goods (CPG) companies. The first deployment is with a large drug retailer and highlights a unique, interactive digital experience. VSBLTY’s ability to collaborate with a major display manufacturer on design and implementation options has accelerated their bringing innovative solutions to CPG clients directly.
The company is in the final stages of signing a partnership agreement with the largest in-store media sales company in the U.S and Canada. This relationship provides speed to market in which VSBLTY solutions can be sold as a media network purchase.
VSBLTY is on the fast track to complete an OEM and global supply and cooperation agreement with one of the world’s most prominent international retail services companies.
The company’s current development efforts with CIC Technologies (http://www.getcictech.com), a full-service technology company specializing in security solutions, represents a strategic product extension. VSBLTY and CIC Technologies are co-developing a cost-effective multifactor authentication system for employee validation with facial recognition.
Latin American Smart City
VSBLTY is in the final testing stages to provide crowd analytics and facial recognition on a massive scale in a key Latin American country.
Hutton says another new, exciting partner manages smart buildings throughout the world. VSBLTY is joining forces with the firm to create the latest software application for enhanced security using its proprietary AI and machine learning technology. The company is also providing a more engaging way to communicate important information to guests and tenants.
The VSBLTY tech team is working on the next generation design of an in-store grocery bunker cooler on behalf of one of the world’s largest international food companies. The firm is adding digital display innovation in time for the barbeque season that features hot dogs and cross promotes complimentary condiments.
Conference Exhibit Partnerships
VSBLTY is participating in Cisco Live (NASDAQ: CSCO) the week of June 9 in San Diego where they will be demonstrating the VSBLTY Vector™ software in a weapons detection use case. And, during the last week of May, at the Sweets & Snacks Expo, in Chicago, VSBLTY was part of the Lighting for Impact (https://www.lightingforimpact.com/) exhibit featuring Mars candy. Lighting for Impact is one of America’s leading providers of LED lighting and power systems for retailers.
Summarizing, Hutton said, “All of us at VSBLTY continue to be excited about our vast potential and energized by the market’s reaction to the exciting new innovations that our software technology is bringing to both retail and security.”
MarketSmart Communications Inc., +1-877-261-4466
CONTACT: Linda Rosanio, 609-472-0877
About VSBLTY (www.vsblty.net)
Headquartered in Philadelphia, VSBLTY (CSE: VSBY) (Frankfurt: 5VS) (OTC: VSBGF) is the world leader in Proactive Digital Display™, which transforms retail and public spaces as well as place-based media networks with SaaS-based audience measurement and security software that uses artificial intelligence and machine learning.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CEST | Pressemelding
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients
Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CEST | Pressemelding
LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe
Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CEST | Pressemelding
Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle
iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CEST | Pressemelding
Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag
Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CEST | Pressemelding
MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad
Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CEST | Pressemelding
Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi